Literature DB >> 2013504

Candida endophthalmitis: clinical presentation, treatment and outcome in 23 patients.

S Schmid1, A C Martenet, O Oelz.   

Abstract

The presumptive diagnosis of Candida endophthalmitis was made in 11 intravenous (i.v.) drug addicts, seven surgical patients and five individuals with no established risk factors. It was based on the clinical symptoms with partial to total visual loss and the findings of a retinohyalitic lesion eventually affecting the entire eye. Empiric antimycotic treatment consisted of i.v. amphotericin B (average cumulative dose 1,580 mg) and i.v. or oral flucytosine (mean cumulative dose 231 g). This treatment resulted in a significant mean improvement of visual acuity from 0.15 to 0.275 during treatment and 0.55 after completion of therapy. Long-term results showed stable scar healing of the inflammatory lesions and stable to improved visual acuity. Transient side effects of treatment included anemia, thrombocytopenia and a rise of serum creatinine. Empiric antimycotic treatment of presumptive Candida endophthalmitis favourably influences the course of this infection. Regular ophthalmological examination of these patients is mandatory.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013504     DOI: 10.1007/bf01643753

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

Review 1.  Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis.

Authors:  J E Edwards; R Y Foos; J Z Montgomerie; L B Guze
Journal:  Medicine (Baltimore)       Date:  1974-01       Impact factor: 1.889

Review 2.  Strategies in the treatment of systemic fungal infections.

Authors:  G Medoff; G S Kobayashi
Journal:  N Engl J Med       Date:  1980-01-17       Impact factor: 91.245

3.  [Mycotic panuveitis (author's transl)].

Authors:  T Wegmann; U Frey; P Speiser
Journal:  Schweiz Rundsch Med Prax       Date:  1979-03-06

4.  [Candida endophthalmitis: diagnosis, course and therapy in 8 patients].

Authors:  D Marugg; A C Martenet; B Morell; O Oelz
Journal:  Schweiz Med Wochenschr       Date:  1985-01-26

5.  Candida endophthalmitis after intravenous drug abuse.

Authors:  G L Aguilar; M S Blumenkrantz; P R Egbert; J P McCulley
Journal:  Arch Ophthalmol       Date:  1979-01

6.  Endogenous endophthalmitis among patients with candidemia.

Authors:  D W Parke; D B Jones; L O Gentry
Journal:  Ophthalmology       Date:  1982-07       Impact factor: 12.079

7.  Candidiasis in cancer patients.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

8.  Systemic candidiasis in cancer patients.

Authors:  A W Maksymiuk; S Thongprasert; R Hopfer; M Luna; V Fainstein; G P Bodey
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

9.  Candida endophthalmitis in a heroin addict: a case report.

Authors:  J F Salmon; B M Partridge; D J Spalton
Journal:  Br J Ophthalmol       Date:  1983-05       Impact factor: 4.638

10.  Candida endophthalmitis in heroin addicts.

Authors:  M Hogeweg; P T de Jong
Journal:  Doc Ophthalmol       Date:  1983-02-28       Impact factor: 2.379

View more
  4 in total

1.  Management of deep Candida infection in surgical and intensive care unit patients. British Society for Antimicrobial Chemotherapy Working Party.

Authors: 
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

2.  Candida endophthalmitis in non-neutropenic critically ill patients.

Authors:  J Nolla-Salas; A Sitges-Serra; C León; M V de la Torre; H Sancho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

3.  Rapid detection and identification of Candida, Aspergillus, and Fusarium species in ocular samples using nested PCR.

Authors:  E E Jaeger; N M Carroll; S Choudhury; A A Dunlop; H M Towler; M M Matheson; P Adamson; N Okhravi; S Lightman
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

4.  Hematogenous endophthalmitis in a patient with candidemia.

Authors:  S K Na; K J Park; H J Kim; S C Lee
Journal:  Korean J Intern Med       Date:  1997-06       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.